Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. (“Hims”) and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization’ and are disseminating deceptive marketing that put patient safety at risk.”

On this news, Novo Nordisk’s stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors.

Then, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s.

On this news, Novo Nordisk’s stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors further.

Contact Us To Participate or Learn More:

If you purchased Novo Nordisk securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250730278870/en/